Palliative Care for Patients with End-Stage Liver Disease.

[1]  A. de Gottardi,et al.  Consensus care recommendations for alfapump® in cirrhotic patients with refractory or recurrent ascites , 2022, BMC Gastroenterology.

[2]  E. Tapper,et al.  Review article: current and emerging therapies for the management of cirrhosis and its complications , 2022, Alimentary pharmacology & therapeutics.

[3]  J. Bajaj,et al.  Gut Microbiome and Alcohol-associated Liver Disease. , 2022, Journal of clinical and experimental hepatology.

[4]  H. Yoshiji,et al.  Baveno VII - Renewing consensus in portal hypertension. , 2021, Journal of hepatology.

[5]  N. Aksan,et al.  MELD-Na Accurately Predicts 6-Month Mortality in Patients With Decompensated Cirrhosis , 2021, Journal of clinical gastroenterology.

[6]  M. Kumar,et al.  Tadalafil improves erectile dysfunction and quality of life in men with cirrhosis: a randomized double blind placebo controlled trial , 2021, Hepatology International.

[7]  Rizwan Ahamed,et al.  Friend or Foe? Spontaneous Portosystemic Shunts in Cirrhosis—Current Understanding and Future Prospects , 2021, Canadian journal of gastroenterology & hepatology.

[8]  J. Lai,et al.  Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases , 2021, Hepatology.

[9]  H. Yoshiji,et al.  Evidence‐based clinical practice guidelines for liver cirrhosis 2020 , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  P. Kamath,et al.  Acute-on-chronic liver failure: A distinct clinical syndrome. , 2021, Journal of hepatology.

[11]  N. Freemantle,et al.  A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. , 2021, The New England journal of medicine.

[12]  M. Armstrong,et al.  Assessment of the Frail Patient With End‐Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and Disability , 2021, Hepatology communications.

[13]  C. Benítez,et al.  Frailty and reduced gait speed are independently related to mortality of cirrhotic patients in long-term follow-up. , 2021, Annals of hepatology.

[14]  Rizwan Ahamed,et al.  Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update , 2020, World journal of gastroenterology.

[15]  J. Bosch,et al.  Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications , 2020, United European gastroenterology journal.

[16]  P. Williams,et al.  Randomised clinical trial: palliative long‐term abdominal drains vs large‐volume paracentesis in refractory ascites due to cirrhosis , 2020, Alimentary pharmacology & therapeutics.

[17]  P. Tatum,et al.  Hospice and Palliative Care: An Overview. , 2020, The Medical clinics of North America.

[18]  G. Garcia‐Tsao,et al.  Sodium‐Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes , 2020, Hepatology.

[19]  J. Bosch,et al.  Beta-blockers in cirrhosis: Evidence-based indications and limitations , 2019, JHEP reports.

[20]  D. Ganger,et al.  Association Between Liver Transplant Wait-list Mortality and Frailty Based on Body Mass Index. , 2019, JAMA surgery.

[21]  M. Serper,et al.  Current Knowledge, Barriers to Implementation, and Future Directions in Palliative Care for End‐Stage Liver Disease , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  E. Tapper,et al.  Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis , 2019, Digestive Diseases and Sciences.

[23]  I. Higginson,et al.  Symptom prevalence and quality of life of patients with end-stage liver disease: A systematic review and meta-analysis , 2018, Palliative medicine.

[24]  G. McCaughan,et al.  Frailty in advanced liver disease , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[25]  M. Heneghan,et al.  Palliative care in end‐stage liver disease: Time to do better? , 2018, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[26]  Devika R. Jutagir,et al.  Psychiatric Comorbidity, Health-Related Quality of Life, and Mental Health Service Utilization Among Patients Awaiting Liver Transplant. , 2018, Journal of pain and symptom management.

[27]  M. Rakoski,et al.  Pain management in patients with cirrhosis , 2018, Clinical liver disease.

[28]  A. Gasbarrini,et al.  Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial , 2018, The Lancet.

[29]  Jennifer M. Kapo,et al.  Palliative care in decompensated cirrhosis: A review , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[30]  Shari S. Rogal,et al.  The Assessment and Management of Pain in Cirrhosis , 2018, Current Hepatology Reports.

[31]  R. Jalan,et al.  Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study , 2018, Quality of Life Research.

[32]  S. Saab,et al.  Palliative Care and Health Care Utilization for Patients With End‐Stage Liver Disease at the End of Life , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[33]  J. McPeake,et al.  Long-term outcome of patients with liver cirrhosis admitted to a general intensive care unit , 2017, Annals of Intensive Care.

[34]  P. Angus,et al.  Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. , 2016, Journal of hepatology.

[35]  J. Verne,et al.  Integration of palliative and supportive care in the management of advanced liver disease: development and evaluation of a prognostic screening tool and supportive care intervention , 2016, Frontline Gastroenterology.

[36]  J. Tulsky,et al.  Effect of Palliative Care-Led Meetings for Families of Patients With Chronic Critical Illness: A Randomized Clinical Trial. , 2016, JAMA.

[37]  Caroline C. Jadlowiec,et al.  Liver transplantation: Current status and challenges. , 2016, World journal of gastroenterology.

[38]  Christopher Moore.  Evaluation and management of insomnia, muscle cramps, fatigue, and itching in cirrhotic patients , 2016, Clinical liver disease.

[39]  G. Caletti,et al.  Palliative care in patients with liver cirrhosis: it is the time to deal with the burden , 2015, BMJ Supportive & Palliative Care.

[40]  A. Larson.  Palliative Care for Patients with End-Stage Liver Disease , 2015, Current Gastroenterology Reports.

[41]  H. Lui,et al.  Change in model for end-stage liver disease score at two weeks, as an indicator of mortality or liver transplantation at 60 days in acute-on-chronic liver failure , 2014, Gastroenterology report.

[42]  M. Allman-Farinelli,et al.  Systematic review: the treatment of muscle cramps in patients with cirrhosis , 2014, Alimentary pharmacology & therapeutics.

[43]  P. Tandon,et al.  Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  Hyung Joon Kim,et al.  Important predictor of mortality in patients with end-stage liver disease , 2013, Clinical and molecular hepatology.

[45]  S. Lamba,et al.  Changing end-of-life care practice for liver transplant service patients: structured palliative care intervention in the surgical intensive care unit. , 2012, Journal of pain and symptom management.

[46]  T. Seufferlein,et al.  Prognostic indicators of survival in patients with compensated and decompensated cirrhosis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[47]  U. Jäger,et al.  How I treat autoimmune hemolytic anemias in adults. , 2010, Blood.

[48]  W. Stremmel,et al.  Limitations of the MELD score in predicting mortality or need for removal from waiting list in patients awaiting liver transplantation , 2009, BMC gastroenterology.

[49]  S. Asch,et al.  Development and Initial Validation of the PEG, a Three-item Scale Assessing Pain Intensity and Interference , 2009, Journal of General Internal Medicine.

[50]  W. Kim,et al.  The model for end‐stage liver disease (MELD) , 2007, Hepatology.

[51]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[52]  Shinn-Jang Hwang,et al.  Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study , 2000, American Journal of Gastroenterology.